Antibiotic susceptibility and treatment of brucellosis.
Brucellosis, a zoonotic infection caused by the genus Brucellae, is an ancient condition linked to the consumption of milk and milk products. The disease has global importance due to its impact. Therapeutic options for brucellosis rely mostly on uncontrolled, nonrandomized, non-blinded studies. The choice and duration of therapy are related to patient characteristics and the presence of a focal disease. The usual therapy of acute brucellosis is a combination of doxycycline plus rifampicin for 6 weeks. An aminoglycoside could be substituted for rifampin for the initial week of combination therapy. Other alternatives include a combination of doxycycline plus trimethoprim-sulfamethoxazole, or a fluoroquinolone plus rifampicin. The presence of spondylitis or endocarditis usually indicates that the required treatment will be of a longer duration or a combination of therapy. The article has the discussion of some recent patents related to antibiotic susceptibility and Brucellosis.
Saudi Aramco Medical Services Organization, Dhahran, Kingdom of Saudi Arabia.
Jaffar A
JA
Al-Tawfiq
Ziad A
ZA
Memish
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001850:Bone Diseases, Infectious / Q000188:drug therapy / Q000382:microbiology; D002006:Brucellosis / Q000150:complications* / Q000188:drug therapy*; D004318:Doxycycline / Q000008:administration & dosage / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D010330:Patents as Topic; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013166:Spondylitis / Q000188:drug therapy / Q000382:microbiology; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D004318:Doxycycline; D012293:Rifampin